NPXe Limited (“NPXe”), a Phase III pharmaceutical and drug delivery device company developing XENEX™ (xenon gas for inhalation) for neuro- and cardio-protection and improvement in survival for post-cardiac arrest syndrome (PCAS) patients, announced that it has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). NPXe has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
Read the full article: NPXe Files Voluntary Chapter 11 to Implement 363 Asset Sale //
Source: https://www.prnewswire.com/news-releases/npxe-files-voluntary-chapter-11-to-implement-363-asset-sale-300979598.html